BR112015012507A2 - marcadores de diagnóstico para tratar distúrbios de proliferação celular com inibidores da telomerase - Google Patents

marcadores de diagnóstico para tratar distúrbios de proliferação celular com inibidores da telomerase

Info

Publication number
BR112015012507A2
BR112015012507A2 BR112015012507A BR112015012507A BR112015012507A2 BR 112015012507 A2 BR112015012507 A2 BR 112015012507A2 BR 112015012507 A BR112015012507 A BR 112015012507A BR 112015012507 A BR112015012507 A BR 112015012507A BR 112015012507 A2 BR112015012507 A2 BR 112015012507A2
Authority
BR
Brazil
Prior art keywords
cell proliferation
diagnostic markers
individuals
proliferation disorders
telomerase inhibitors
Prior art date
Application number
BR112015012507A
Other languages
English (en)
Other versions
BR112015012507B1 (pt
BR112015012507A8 (pt
Inventor
Burington Bart
Bassett Ekaterina
Wang Hui
Eng Kevin
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,035 external-priority patent/US9200327B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of BR112015012507A2 publication Critical patent/BR112015012507A2/pt
Publication of BR112015012507A8 publication Critical patent/BR112015012507A8/pt
Publication of BR112015012507B1 publication Critical patent/BR112015012507B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)

Abstract

resumo “marcadores de diagnóstico para tratar distúrbios de proliferação celular com inibidores da telomerase” são aqui proporcionados métodos para a identificação de indivíduos com diagnóstico de uma patologia proliferativa celular que irá beneficiar do tratamento com um composto inibidor de telomerase. além disso proporcionam-se aqui métodos para tratar estes indivíduos com compostos inibidores da telomerase. os métodos compreendem os indivíduos que irão beneficiar de identificação a partir do referido tratamento com base na duração média relativa dos telómeros nas células cancerosas de tais indivíduos.
BR112015012507-7A 2012-11-30 2013-11-27 Método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer BR112015012507B1 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261732263P 2012-11-30 2012-11-30
US61/732.263 2012-11-30
US201361780851P 2013-03-13 2013-03-13
US13/802,035 US9200327B2 (en) 2012-11-30 2013-03-13 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US61/780.851 2013-03-13
US13/802.035 2013-03-13
US201361798478P 2013-03-15 2013-03-15
US61/798.478 2013-03-15
US201361809228P 2013-04-05 2013-04-05
US61/809.228 2013-04-05
PCT/US2013/072302 WO2014085632A1 (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Publications (3)

Publication Number Publication Date
BR112015012507A2 true BR112015012507A2 (pt) 2017-07-11
BR112015012507A8 BR112015012507A8 (pt) 2019-10-08
BR112015012507B1 BR112015012507B1 (pt) 2023-03-07

Family

ID=50828470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012507-7A BR112015012507B1 (pt) 2012-11-30 2013-11-27 Método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer

Country Status (24)

Country Link
EP (3) EP3882355B1 (pt)
JP (2) JP6359028B2 (pt)
KR (3) KR20210112394A (pt)
CN (2) CN104937110A (pt)
AU (3) AU2013352105B2 (pt)
BR (1) BR112015012507B1 (pt)
CA (1) CA2892445C (pt)
CY (1) CY1124140T1 (pt)
DK (2) DK3495495T3 (pt)
ES (3) ES2703914T3 (pt)
HK (1) HK1215874A1 (pt)
HR (2) HRP20181991T1 (pt)
HU (1) HUE054053T2 (pt)
IL (3) IL282112B (pt)
LT (2) LT3495495T (pt)
MX (1) MX362094B (pt)
NZ (2) NZ748624A (pt)
PL (2) PL2925889T3 (pt)
PT (2) PT2925889T (pt)
RS (1) RS61513B1 (pt)
SG (1) SG11201504209YA (pt)
SI (2) SI2925889T1 (pt)
WO (1) WO2014085632A1 (pt)
ZA (2) ZA201900759B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3719139B1 (en) 2008-10-17 2022-11-30 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2018207952A1 (ja) * 2017-05-12 2018-11-15 国立大学法人九州大学 発毛及び／又は育毛用組成物
CN112770783A (zh) * 2018-07-31 2021-05-07 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
GB201818792D0 (en) * 2018-11-19 2019-01-02 Telonostix Ltd Compounds for telomere length-related treatment of cancer
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602B (zh) * 2020-09-28 2024-06-11 中国科学院上海营养与健康研究所 靶向tert在调节皮肤及毛发色素中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
JPH11276182A (ja) * 1997-12-26 1999-10-12 Chugai Pharmaceut Co Ltd 逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7695904B2 (en) 2002-01-31 2010-04-13 University Of Utah Research Foundation Reducing non-target nucleic acid dependent amplifications: amplifying repetitive nucleic acid sequences
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
US9169516B2 (en) 2003-01-24 2015-10-27 University Of Utah Research Foundation Methods of predicting mortality risk by determining telomere length
BRPI0414222B8 (pt) * 2003-09-09 2021-05-25 Geron Corp compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
CA2602562C (en) * 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
EP3719139B1 (en) * 2008-10-17 2022-11-30 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
CN107083444B (zh) 2008-12-22 2023-03-14 犹他大学研究基金会 单色多重定量pcr
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
EP2691775B1 (en) * 2011-03-28 2017-12-13 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

Also Published As

Publication number Publication date
AU2022202808A1 (en) 2022-05-19
JP2018099127A (ja) 2018-06-28
MX2015006538A (es) 2015-09-23
BR112015012507B1 (pt) 2023-03-07
ES2703914T3 (es) 2019-03-13
KR102174763B1 (ko) 2020-11-06
EP3495495A1 (en) 2019-06-12
ZA202101317B (en) 2023-03-29
BR112015012507A8 (pt) 2019-10-08
HK1215874A1 (zh) 2016-09-23
PT2925889T (pt) 2018-12-12
LT3495495T (lt) 2021-02-25
DK3495495T3 (da) 2021-03-22
IL270636B (en) 2021-04-29
SI3495495T1 (sl) 2021-07-30
IL282112B (en) 2022-09-01
JP6359028B2 (ja) 2018-07-18
HRP20210451T1 (hr) 2021-05-14
CN104937110A (zh) 2015-09-23
PL3495495T3 (pl) 2021-08-30
EP3882355C0 (en) 2023-12-20
WO2014085632A1 (en) 2014-06-05
AU2019283840A1 (en) 2020-01-23
AU2013352105B2 (en) 2019-09-19
EP2925889A1 (en) 2015-10-07
RS61513B1 (sr) 2021-03-31
EP2925889B1 (en) 2018-09-05
ES2865446T3 (es) 2021-10-15
NZ748624A (en) 2020-08-28
CN111494629A (zh) 2020-08-07
CY1124140T1 (el) 2022-05-27
SG11201504209YA (en) 2015-06-29
IL239035A0 (en) 2015-07-30
EP3882355A1 (en) 2021-09-22
CA2892445C (en) 2022-06-28
ES2972330T3 (es) 2024-06-12
MX362094B (es) 2019-01-07
NZ708654A (en) 2020-04-24
EP3882355B1 (en) 2023-12-20
HRP20181991T1 (hr) 2019-03-08
HUE054053T2 (hu) 2021-08-30
SI2925889T1 (sl) 2019-01-31
IL239035B (en) 2020-09-30
KR102348240B1 (ko) 2022-01-10
PL2925889T3 (pl) 2019-02-28
JP2016501523A (ja) 2016-01-21
LT2925889T (lt) 2018-12-27
PT3495495T (pt) 2021-03-22
EP3495495B1 (en) 2020-12-23
KR20200128446A (ko) 2020-11-12
EP2925889A4 (en) 2016-06-15
IL282112A (en) 2021-05-31
KR20150091491A (ko) 2015-08-11
DK2925889T3 (da) 2019-01-02
CA2892445A1 (en) 2014-06-05
ZA201900759B (en) 2020-10-28
AU2013352105A1 (en) 2015-06-18
KR20210112394A (ko) 2021-09-14

Similar Documents

Publication Publication Date Title
BR112015012507A2 (pt) marcadores de diagnóstico para tratar distúrbios de proliferação celular com inibidores da telomerase
BR112018073786A2 (pt) métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk
AR080643A1 (es) Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
BR112019006041A2 (pt) métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112018077136A2 (pt) composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
CL2015002194A1 (es) Inhbidores de erk y sus usos
BR112018010933A2 (pt) anticorpos multiespecíficos
BR112015025944A8 (pt) composição compreendendo inibidores do caminho do hedgehog e uso dos referidos inibidores
CR20150217A (es) Inhibidores de histona demetilasas
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
CR20150242A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
BR112014009276A8 (pt) uso de inibidores de tirosina quinase de bruton (btk)
TR201812261T4 (tr) Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
MX2015001081A (es) Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
BR112015021423A2 (pt) métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112018002427A2 (pt) terapias de combinação para tratamento do câncer
WO2015011282A8 (en) Method for identifying modulators of bcrp/abcg2-mediated atp release and use of said modulators for treating diseases
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GERON CORPORATION (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2013, OBSERVADAS AS CONDICOES LEGAIS